WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback